-
Antimicrobials in Ventilated Patients with Multidrug Resistant Organisms—To Treat or Not to Treat?
-
Stapled Peptides Potentiate Antibiotic Treatment in Vivo
-
New Strategies in Antibiotic Prophylaxis in Transrectal Prostate Biopsies. What Changed after EMA Restriction for Fluoroquinolones
-
Simple and Smart: 10 Minute Peer-to-Peer Teaching as an Effective Antibiotic Stewardship Intervention
-
Antimicrobial Activity Enhancers
Journal Description
Antibiotics
Antibiotics
is a peer-reviewed, open access journal on all aspects of antibiotics, published monthly online by MDPI.
- Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
- High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and many other databases.
- Journal Rank: JCR - Q2 (Infectious Diseases) / CiteScore - Q2 (General Pharmacology, Toxicology and Pharmaceutics)
- Rapid Publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 14.5 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the second half of 2021).
- Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
Impact Factor:
4.639 (2020)
;
5-Year Impact Factor:
4.849 (2020)
Latest Articles
Co-Delivery of Nano-Silver and Vancomycin via Silica Nanopollens for Enhanced Antibacterial Functions
Antibiotics 2022, 11(5), 685; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050685 - 18 May 2022
Abstract
Infectious diseases caused by bacteria have led to a great threat to public health. With the significant advances in nanotechnology in recent decades, nanomaterials have emerged as a powerful tool to boost antibacterial performance due to either intrinsic bactericidal properties or by enhancing
[...] Read more.
Infectious diseases caused by bacteria have led to a great threat to public health. With the significant advances in nanotechnology in recent decades, nanomaterials have emerged as a powerful tool to boost antibacterial performance due to either intrinsic bactericidal properties or by enhancing the delivery efficiency of antibiotics for effective pathogen killing. Vancomycin, as one of the most widely employed antimicrobial peptides, has a potent bactericidal activity, but at the same time shows a limited bioavailability. Silver nanoparticles have also been extensively explored and were found to have a well-recognized antibacterial activity and limited resistance potential; however, how to prevent nanosized Ag particles from aggregation in biological conditions is challenging. In this study, we aimed to combine the advantages of both vancomycin and nano-Ag for enhanced bacterial killing, where both antibacterial agents were successfully loaded onto a silica nanoparticle with a pollen-like morphology. The morphology of nano-Ag-decorated silica nanopollens was characterized using transmission electron microscopy and elemental mapping through energy dispersive spectroscopy. Silver nanoparticles with a size of 10–25 nm were observed as well-distributed on the surface of silica nanoparticles of around 200 nm. The unique design of a spiky morphology of silica nano-carriers promoted the adhesion of nanoparticles towards bacterial surfaces to promote localized drug release for bacterial killing, where the bacterial damage was visualized through scanning electron microscopy. Enhanced bactericidal activity was demonstrated through this co-delivery of vancomycin and nano-Ag, decreasing the minimum inhibition concentration (MIC) towards E. coli and S. epidermidis down to 15 and 10 µg/mL. This study provides an efficient antimicrobial nano-strategy to address potential bacterial infections.
Full article
(This article belongs to the Special Issue Antibiotic-Free Antibacterial Strategies Enabled by Nanomaterials)
Open AccessArticle
Multi Evaluation of a Modified GoldNano Carb Test for Carbapenemase Detection in Clinical Isolates of Gram-Negative Bacilli
by
, , , , , , , , , , , , , and
Antibiotics 2022, 11(5), 684; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050684 - 18 May 2022
Abstract
Carbapenemase-producing Gram-negative bacteria have been increasingly reported. Simple and sensitive methods for carbapenemase detection are still needed. In this study, a gold nanoparticle (AuNP) solution was modified by the addition of zinc sulfate (ZnSO4) for improving the conventional GoldNano Carb (cGoldC)
[...] Read more.
Carbapenemase-producing Gram-negative bacteria have been increasingly reported. Simple and sensitive methods for carbapenemase detection are still needed. In this study, a gold nanoparticle (AuNP) solution was modified by the addition of zinc sulfate (ZnSO4) for improving the conventional GoldNano Carb (cGoldC) test, and the modified GoldC (mGoldC) test was then evaluated for phenotypic detection of carbapenemase production in Gram-negative bacilli clinical isolates. ZnSO4 was added to give final concentrations of 0.25, 0.5, 0.75, and 1 mM. The performance of the mGoldC test was evaluated in Enterobacterales, Acinetobacter spp., and Pseudomonas aeruginosa isolates from six hospitals in different regions using polymerase chain reaction (PCR) as a gold standard. The AuNP solution with 0.25 mM ZnSO4 was used for the mGoldC test. Evaluation of the mGoldC test in 495 Enterobacterales, 212 Acinetobacter spp., and 125 P. aeruginosa isolates (including 444 carbapenemase producers and 388 non-carbapenemase producers) revealed sensitivity, specificity, a positive likelihood ratio, and a negative likelihood ratio of 98.6%, 98.2%, 54.7, and 0.01, respectively. This test is fast, easy to perform, cost-effective (~0.25 USD per test), and highly sensitive and specific for routine carbapenemase detection, thus leading to effective antimicrobial therapy and infection control measures.
Full article
(This article belongs to the Topic Emerging Material-Based Approaches to Chronic and Infectious Diseases)
►▼
Show Figures

Figure 1
Open AccessArticle
Leucyl-tRNA Synthetase Inhibitor, D-Norvaline, in Combination with Oxacillin, Is Effective against Methicillin-Resistant Staphylococcus aureus
by
, , , , , , , , , and
Antibiotics 2022, 11(5), 683; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050683 - 18 May 2022
Abstract
►▼
Show Figures
Methicillin-resistant Staphylococcus aureus (MRSA) is a pathogenic bacterium that causes severe diseases in humans. For decades, MRSA has acquired substantial resistance against conventional antibiotics through regulatory adaptation, thereby posing a challenge for treating MRSA infection. One of the emerging strategies to combat MRSA
[...] Read more.
Methicillin-resistant Staphylococcus aureus (MRSA) is a pathogenic bacterium that causes severe diseases in humans. For decades, MRSA has acquired substantial resistance against conventional antibiotics through regulatory adaptation, thereby posing a challenge for treating MRSA infection. One of the emerging strategies to combat MRSA is the combinatory use of antibacterial agents. Based on the dramatic change in phospholipid fatty acid (PLFA) composition of MRSA in previous results, this study investigated branched-chain amino acid derivatives (precursors of fatty acid synthesis of cell membrane) and discovered the antimicrobial potency of D-norvaline. The compound, which can act synergistically with oxacillin, is among the three leucine-tRNA synthetase inhibitors with high potency to inhibit MRSA cell growth and biofilm formation. PLFA analysis and membrane properties revealed that D-norvaline decreased the overall amount of PLFA, increasing the fluidity and decreasing the hydrophobicity of the bacterial cell membrane. Additionally, we observed genetic differences to explore the response to D-norvaline. Furthermore, deletion mutants and clinically isolated MRSA strains were treated with D-norvaline. The study revealed that D-norvaline, with low concentrations of oxacillin, was effective in killing several MRSA strains. In summary, our findings provide a new combination of aminoacyl-tRNA synthetase inhibitor D-norvaline and oxacillin, which is effective against MRSA.
Full article

Figure 1
Open AccessArticle
Exploration of Trends in Antimicrobial Use and Their Determinants Based on Dispensing Information Collected from Pharmacies throughout Japan: A First Report
by
, , , , , , , , , , , , , , , , and
Antibiotics 2022, 11(5), 682; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050682 - 18 May 2022
Abstract
The purpose of this study was to evaluate the defined daily doses (DDD)/1000 prescriptions/month (DPM) as a new indicator that can be used in pharmacies, and to describe antimicrobial use patterns in pharmacies nationwide in Japan. Dispensing volumes, number of prescriptions received, and
[...] Read more.
The purpose of this study was to evaluate the defined daily doses (DDD)/1000 prescriptions/month (DPM) as a new indicator that can be used in pharmacies, and to describe antimicrobial use patterns in pharmacies nationwide in Japan. Dispensing volumes, number of prescriptions received, and facility information were obtained from 2638 pharmacies that participated in a survey. DPM was calculated based on the dispensing volume and number of prescriptions, which are routinely collected data that are simple to use. Use of third-generation cephalosporins, quinolones, and macrolides in pharmacies that received prescriptions primarily from hospitals or clinics decreased from January 2019 to January 2021. In particular, the antimicrobial use was higher in otorhinolaryngology departments than in other departments, despite a decrease in the antimicrobial use. In the linear multiple regression analysis, otorhinolaryngology department was independently associated with the third-generation cephalosporin, quinolone, and macrolide prescription in all periods. This study reveals for the first-time trends in antimicrobial use through a new indicator using the volume of drugs dispensed in pharmacies throughout Japan. Antimicrobial use differed by the medical department, suggesting the need to target interventions according to the department type.
Full article
(This article belongs to the Special Issue Antimicrobial Prescribing and Antimicrobial Use in Healthcare Settings)
►▼
Show Figures

Figure 1
Open AccessArticle
Phytochemical Composition, Antioxidant and Antifungal Activity of Thymus capitatus, a Medicinal Plant Collected from Northern Morocco
by
, , , , , , , , and
Antibiotics 2022, 11(5), 681; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050681 - 18 May 2022
Abstract
Thymus capitatus is a Mediterranean endemic plant commonly known as “Zaïtra” in northern Morocco. As T. capitatus is widely used in traditional medicine and food, this present work aims to investigate the chemical compositions and biological activities of the T. capitatus leaves essential
[...] Read more.
Thymus capitatus is a Mediterranean endemic plant commonly known as “Zaïtra” in northern Morocco. As T. capitatus is widely used in traditional medicine and food, this present work aims to investigate the chemical compositions and biological activities of the T. capitatus leaves essential oil (TcLEO), acetonic (TcLAE), and methanolic extract (TcLME). The spectrophotometric determination demonstrated that T. capitatus is a natural source rich in phenolic contents (TPC) and flavonoid contents (TFC) and that TcLME revealed the highest TPC and TFC than TcLAE and TcLEO. The LC-MS analysis of phenolic compounds showed that paraben acid was predominant in both TcLME and TcLAE, followed by cinnamic acid and p-hydroxybenzoic acid. GC-MS analysis of the TcLEO revealed the presence of a total of 10 compounds, which were predominated by carvacrol. The antioxidant activity by ORAC was observed to be significantly higher in TcLEO and TcLAE than in TcLME. All samples used to assess DNA degradation effectively prevented DNA oxidation and, at the same time, had a prooxidant effect. The genotoxicity test showed that the T. capitatus were devoid of any mutagenic activity. Concerning antifungal activity, all samples were able to inhibit the growth of all microorganisms tested at low concentrations. TcLAE showed higher activity than TcLME, and in general, dermatophytes were more susceptible, being Microsporum canis the most sensitive one. Overall, the results obtained from this study confirm the wide uses of T. capitatus. Furthermore, the finding results suggest that the T. capitatus essential oil and extracts can be highly useful for pharmaceutical industries.
Full article
(This article belongs to the Special Issue Recent Advances in Antimicrobial Drug Discovery)
►▼
Show Figures

Figure 1
Open AccessArticle
Identification of Therapeutic Targets in an Emerging Gastrointestinal Pathogen Campylobacter ureolyticus and Possible Intervention through Natural Products
by
, , , , , and
Antibiotics 2022, 11(5), 680; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050680 - 18 May 2022
Abstract
Campylobacter ureolyticus is a Gram-negative, anaerobic, non-spore-forming bacteria that causes gastrointestinal infections. Being the most prevalent cause of bacterial enteritis globally, infection by this bacterium is linked with significant morbidity and mortality in children and immunocompromised patients. No information on pan-therapeutic drug targets
[...] Read more.
Campylobacter ureolyticus is a Gram-negative, anaerobic, non-spore-forming bacteria that causes gastrointestinal infections. Being the most prevalent cause of bacterial enteritis globally, infection by this bacterium is linked with significant morbidity and mortality in children and immunocompromised patients. No information on pan-therapeutic drug targets for this species is available yet. In the current study, a pan-genome analysis was performed on 13 strains of C. ureolyticus to prioritize potent drug targets from the identified core genome. In total, 26 druggable proteins were identified using subtractive genomics. To the best of the authors’ knowledge, this is the first report on the mining of drug targets in C. ureolyticus. UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) was selected as a promiscuous pharmacological target for virtual screening of two bacterial-derived natural product libraries, i.e., postbiotics (n = 78) and streptomycin (n = 737) compounds. LpxC inhibitors from the ZINC database (n = 142 compounds) were also studied with reference to LpxC of C. ureolyticus. The top three docked compounds from each library (including ZINC26844580, ZINC13474902, ZINC13474878, Notoginsenoside St-4, Asiaticoside F, Paraherquamide E, Phytoene, Lycopene, and Sparsomycin) were selected based on their binding energies and validated using molecular dynamics simulations. To help identify potential risks associated with the selected compounds, ADMET profiling was also performed and most of the compounds were considered safe. Our findings may serve as baseline information for laboratory studies leading to the discovery of drugs for use against C. ureolyticus infections.
Full article
(This article belongs to the Special Issue Clinical Pharmacology and Pharmacy of Antimicrobial Agents)
►▼
Show Figures

Figure 1
Open AccessArticle
A Soil-Isolated Streptomyces spororaveus Species Produces a High-Molecular-Weight Antibiotic AF1 against Fungi and Gram-Positive Bacteria
Antibiotics 2022, 11(5), 679; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050679 - 18 May 2022
Abstract
The overuse of antibiotics has resulted in the emergence of antibiotic resistance, not only in bacteria but also in fungi. Streptomyces are known to produce numerous secondary metabolites including clinically useful antibiotics. In this study, we screened for antibiotic-producing actinobacteria from soils in
[...] Read more.
The overuse of antibiotics has resulted in the emergence of antibiotic resistance, not only in bacteria but also in fungi. Streptomyces are known to produce numerous secondary metabolites including clinically useful antibiotics. In this study, we screened for antibiotic-producing actinobacteria from soils in Taipei and discovered a Streptomyces strain SC26 that displayed antimicrobial activities against Gram-positive bacteria and fungi, but the compounds are heat-labile. Upon UV mutagenesis, a late-sporulation mutant SC263 was isolated with the same antibiotic spectrum but increased in thermostability. The nature of the antibiotic is not clear, but its activity was resistant to proteolytic, nucleolytic and pancreatic digestions, and was retained by the 100 kDa membrane during filtration. To gather more information on SC263, the genome was sequenced, which produced three contigs with a total of 8.2 Mb and was assigned to the species of Streptomyces spororaveus based on the average nucleotide identity to the reference species S. spororaveus NBRC 15456.
Full article
(This article belongs to the Special Issue Anti-microbial Activity of Metabolites Isolated from Fungi)
►▼
Show Figures

Figure 1
Open AccessEditorial
Multi-Drug-Resistant Gram-Negative Microorganisms: Epidemiology, Treatment and Alternative Approach
Antibiotics 2022, 11(5), 678; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050678 - 18 May 2022
Abstract
The presence of enzymes such as Extended-Spectrum β-lactamase (ESBL) and carbapenemases (KPCs, Metallo β-lactamases and OXA) constitutes the principal resistance mechanism to antibiotics [...]
Full article
(This article belongs to the Special Issue Multi-Drug Resistant Gram-Negative Microorganisms: Epidemiology, Treatment and Alternative Approach)
Open AccessArticle
The Specific Capsule Depolymerase of Phage PMK34 Sensitizes Acinetobacter baumannii to Serum Killing
by
, , , , , , , , , , and
Antibiotics 2022, 11(5), 677; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050677 - 17 May 2022
Abstract
The rising antimicrobial resistance is particularly alarming for Acinetobacter baumannii, calling for the discovery and evaluation of alternatives to treat A. baumannii infections. Some bacteriophages produce a structural protein that depolymerizes capsular exopolysaccharide. Such purified depolymerases are considered as novel antivirulence compounds.
[...] Read more.
The rising antimicrobial resistance is particularly alarming for Acinetobacter baumannii, calling for the discovery and evaluation of alternatives to treat A. baumannii infections. Some bacteriophages produce a structural protein that depolymerizes capsular exopolysaccharide. Such purified depolymerases are considered as novel antivirulence compounds. We identified and characterized a depolymerase (DpoMK34) from Acinetobacter phage vB_AbaP_PMK34 active against the clinical isolate A. baumannii MK34. In silico analysis reveals a modular protein displaying a conserved N-terminal domain for anchoring to the phage tail, and variable central and C-terminal domains for enzymatic activity and specificity. AlphaFold-Multimer predicts a trimeric protein adopting an elongated structure due to a long α-helix, an enzymatic β-helix domain and a hypervariable 4 amino acid hotspot in the most ultimate loop of the C-terminal domain. In contrast to the tail fiber of phage T3, this hypervariable hotspot appears unrelated with the primary receptor. The functional characterization of DpoMK34 revealed a mesophilic enzyme active up to 50 °C across a wide pH range (4 to 11) and specific for the capsule of A. baumannii MK34. Enzymatic degradation of the A. baumannii MK34 capsule causes a significant drop in phage adsorption from 95% to 9% after 5 min. Although lacking intrinsic antibacterial activity, DpoMK34 renders A. baumannii MK34 fully susceptible to serum killing in a serum concentration dependent manner. Unlike phage PMK34, DpoMK34 does not easily select for resistant mutants either against PMK34 or itself. In sum, DpoMK34 is a potential antivirulence compound that can be included in a depolymerase cocktail to control difficult to treat A. baumannii infections.
Full article
(This article belongs to the Special Issue Development of Bacteriophage Derived Lysins and Depolymerases for Therapeutic Purposes in Combating Bacterial Pathogens)
►▼
Show Figures

Graphical abstract
Open AccessArticle
Genetic Resistance Determinants in Clinical Acinetobacter pittii Genomes
Antibiotics 2022, 11(5), 676; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050676 - 17 May 2022
Abstract
Antimicrobial-resistant pathogenic bacteria are an increasing problem in public health, especially in the healthcare environment, where nosocomial infection microorganisms find their niche. Among these bacteria, the genus Acinetobacter which belongs to the ESKAPE pathogenic group harbors different multi-drug resistant (MDR) species that cause
[...] Read more.
Antimicrobial-resistant pathogenic bacteria are an increasing problem in public health, especially in the healthcare environment, where nosocomial infection microorganisms find their niche. Among these bacteria, the genus Acinetobacter which belongs to the ESKAPE pathogenic group harbors different multi-drug resistant (MDR) species that cause human nosocomial infections. Although A. baumannii has always attracted more interest, the close-related species A. pittii is the object of more study due to the increase in its isolation and MDR strains. In this work, we present the genomic analysis of five clinically isolated A. pittii strains from a Spanish hospital, with special attention to their genetic resistance determinants and plasmid structures. All the strains harbored different genes related to β-lactam resistance, as well as different MDR efflux pumps. We also found and described, for the first time in this species, point mutations that seem linked with colistin resistance, which highlights the relevance of this comparative analysis among the pathogenic species isolates.
Full article
(This article belongs to the Special Issue Diversity of Antimicrobial Resistance Genes in Clinical Settings)
►▼
Show Figures

Figure 1
Open AccessArticle
An Evolutionary Conservation and Druggability Analysis of Enzymes Belonging to the Bacterial Shikimate Pathway
by
Antibiotics 2022, 11(5), 675; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050675 - 17 May 2022
Abstract
Enzymes belonging to the shikimate pathway have long been considered promising targets for antibacterial drugs because they have no counterpart in mammals and are essential for bacterial growth and virulence. However, despite decades of research, there are currently no clinically relevant antibacterial drugs
[...] Read more.
Enzymes belonging to the shikimate pathway have long been considered promising targets for antibacterial drugs because they have no counterpart in mammals and are essential for bacterial growth and virulence. However, despite decades of research, there are currently no clinically relevant antibacterial drugs targeting any of these enzymes, and there are legitimate concerns about whether they are sufficiently druggable, i.e., whether they can be adequately modulated by small and potent drug-like molecules. In the present work, in silico analyses combining evolutionary conservation and druggability are performed to determine whether these enzymes are candidates for broad-spectrum antibacterial therapy. The results presented here indicate that the substrate-binding sites of most enzymes in this pathway are suitable drug targets because of their reasonable conservation and druggability scores. An exception was the substrate-binding site of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase, which was found to be undruggable because of its high content of charged residues and extremely high overall polarity. Although the presented study was designed from the perspective of broad-spectrum antibacterial drug development, this workflow can be readily applied to any antimicrobial target analysis, whether narrow- or broad-spectrum. Moreover, this research also contributes to a deeper understanding of these enzymes and provides valuable insights into their properties.
Full article
(This article belongs to the Special Issue Design and Preparation of Antimicrobial Agents)
►▼
Show Figures

Figure 1
Open AccessArticle
The Class A β-Lactamase Produced by Burkholderia Species Compromises the Potency of Tebipenem against a Panel of Isolates from the United States
Antibiotics 2022, 11(5), 674; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050674 - 17 May 2022
Abstract
Tebipenem-pivoxil hydrobromide, an orally bioavailable carbapenem, is currently in clinical development for the treatment of extended-spectrum β-lactamase- and AmpC-producing Enterobacterales. Previously, tebipenem was found to possess antimicrobial activity against the biothreat pathogens, Burkholderia pseudomallei and Burkholderia mallei. Thus, herein, tebipenem was evaluated
[...] Read more.
Tebipenem-pivoxil hydrobromide, an orally bioavailable carbapenem, is currently in clinical development for the treatment of extended-spectrum β-lactamase- and AmpC-producing Enterobacterales. Previously, tebipenem was found to possess antimicrobial activity against the biothreat pathogens, Burkholderia pseudomallei and Burkholderia mallei. Thus, herein, tebipenem was evaluated against a panel of 150 curated strains of Burkholderia cepacia complex (Bcc) and Burkholderia gladioli, pathogens that infect people who are immunocompromised or have cystic fibrosis. Using the provisional susceptibility breakpoint of 0.12 mg/L for tebipenem, 100% of the Bcc and B. gladioli tested as being provisionally resistant to tebipenem. Bcc and B. gladioli possess two inducible chromosomal β-lactamases, PenA and AmpC. Using purified PenA1 and AmpC1, model β-lactamases expressed in Burkholderia multivorans ATCC 17616, PenA1 was found to slowly hydrolyze tebipenem, while AmpC1 was inhibited by tebipenem with a k2/K value of 1.9 ± 0.1 × 103 M−1s−1. In addition, tebipenem was found to be a weak inducer of blaPenA1 expression. The combination of the slow hydrolysis by PenA1 and weak induction of blaPenA1 likely compromises the potency of tebipenem against Bcc and B. gladioli.
Full article
(This article belongs to the Special Issue Antimicrobial Resistance Mechanisms and Antimicrobial Resistance Genes of Pathogens)
►▼
Show Figures

Figure 1
Open AccessArticle
Synergism between the Synthetic Antibacterial and Antibiofilm Peptide (SAAP)-148 and Halicin
by
, , , , , , , and
Antibiotics 2022, 11(5), 673; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050673 - 17 May 2022
Abstract
Recently, using a deep learning approach, the novel antibiotic halicin was discovered. We compared the antibacterial activities of two novel bactericidal antimicrobial agents, i.e., the synthetic antibacterial and antibiofilm peptide (SAAP)-148 with this antibiotic halicin. Results revealed that SAAP-148 was more effective than
[...] Read more.
Recently, using a deep learning approach, the novel antibiotic halicin was discovered. We compared the antibacterial activities of two novel bactericidal antimicrobial agents, i.e., the synthetic antibacterial and antibiofilm peptide (SAAP)-148 with this antibiotic halicin. Results revealed that SAAP-148 was more effective than halicin in killing planktonic bacteria of antimicrobial-resistant (AMR) Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus, especially in biologically relevant media, such as plasma and urine, and in 3D human infection models. Surprisingly, SAAP-148 and halicin were equally effective against these bacteria residing in immature and mature biofilms. As their modes of action differ, potential favorable interactions between SAAP-148 and halicin were investigated. For some specific strains of AMR E. coli and S. aureus synergism between these agents was observed, whereas for other strains, additive interactions were noted. These favorable interactions were confirmed for AMR E. coli in a 3D human bladder infection model and AMR S. aureus in a 3D human epidermal infection model. Together, combinations of these two novel antimicrobial agents hold promise as an innovative treatment for infections not effectively treatable with current antibiotics.
Full article
(This article belongs to the Topic Novel Antimicrobial Agents: Discovery, Design and New Therapeutic Strategies)
►▼
Show Figures

Figure 1
Open AccessArticle
Grapevine Xylem Sap Is a Potent Elicitor of Antibiotic Production in Streptomyces spp.
by
, , , , , , , and
Antibiotics 2022, 11(5), 672; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050672 - 17 May 2022
Abstract
Streptomyces bacteria produce a wide number of antibiotics and antitumor compounds that have attracted the attention of pharmaceutical and biotech companies. In this study, we provide evidence showing that the xylem sap from grapevines has a positive effect on the production of different
[...] Read more.
Streptomyces bacteria produce a wide number of antibiotics and antitumor compounds that have attracted the attention of pharmaceutical and biotech companies. In this study, we provide evidence showing that the xylem sap from grapevines has a positive effect on the production of different antibiotics by several Streptomyces species, including S. ambofaciens ATCC 23877 and S. argillaceus ATCC 12596 among others. The production of several already known compounds was induced: actinomycin D, chromomycin A3, fungichromin B, mithramycin A, etc., and four compounds with molecular formulas not included in the Dictionary of Natural Products (DNP v28.2) were also produced. The molecules present in the xylem sap that acts as elicitors were smaller than 3 kDa and soluble in water and insoluble in ether, ethyl acetate, or methanol. A combination of potassium citrate and di-D-fructose dianhydrides (related to levanbiose or inulobiose) seemed to be the main effectors identified from the active fraction. However, the level of induction obtained in the presence of these compounds mix was weaker and delayed with respect to the one got when using the whole xylem sap or the 3 kDa sap fraction, suggesting that another, not identified, elicitor must be also implied in this induction.
Full article
(This article belongs to the Special Issue Challenges and Opportunities in Antibiotic Biosynthesis and Development)
►▼
Show Figures

Figure 1
Open AccessArticle
Co-Application of Tetramycin and Matrine Improves Resistance of Kiwifruit against Soft Rot Disease and Enhances Its Quality and Amino Acids
Antibiotics 2022, 11(5), 671; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050671 - 17 May 2022
Abstract
Soft rot disease caused by Botryosphaeria dothidea and Phomopsis sp. is the most serious fungal disease of the kiwifruit production area in southwest China. In this work, the role of the co-application of tetramycin and matrine in the resistance of kiwifruit fruits against
[...] Read more.
Soft rot disease caused by Botryosphaeria dothidea and Phomopsis sp. is the most serious fungal disease of the kiwifruit production area in southwest China. In this work, the role of the co-application of tetramycin and matrine in the resistance of kiwifruit fruits against soft rot disease and its effects on development, quality and amino acids of kiwifruit fruits were investigated. The results indicate that matrine exhibited an outstanding toxicity against B. dothidea RF-1 and Phomopsis sp. RF-2 with EC50 values of 0.442 and 0.332 mg kg−1. The foliar co-application of 0.3% tetramycin aqueous solutions (AS) 5000-fold liquid + 0.5% matrine AS 1000-fold liquid could effectively control soft rot disease with a control efficacy of 82.68%, which was significantly (p < 0.05) higher than 75.19% of 0.3% tetramycin AS 5000-fold liquid and significantly (p < 0.01) higher than 68.50% of 0.5% matrine AS 500-fold liquid. Moreover, the co-application of tetramycin and matrine was more effective than tetramycin or matrine alone in improving disease resistance, quality and amino acids of kiwifruit fruits. This study highlights that the co-application of tetramycin and matrine can be used as a practicable, cost-effective and environmentally friendly candidate or alternative approach for controlling soft rot disease of kiwifruit.
Full article
(This article belongs to the Special Issue Usage of Antibiotic in Agriculture and Animal Farming, 2nd Edition)
►▼
Show Figures

Figure 1
Open AccessArticle
C/MIC > 4: A Potential Instrument to Predict the Efficacy of Meropenem
by
, , , , , , , , and
Antibiotics 2022, 11(5), 670; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050670 - 16 May 2022
Abstract
This prospective study aimed to explore the determinants of meropenem trough concentration (Ctrough) in patients with bacterial pneumonia and to investigate the association between its concentration and efficacy. From January 2019 to December 2019, patients with pulmonary infections were prospectively enrolled
[...] Read more.
This prospective study aimed to explore the determinants of meropenem trough concentration (Ctrough) in patients with bacterial pneumonia and to investigate the association between its concentration and efficacy. From January 2019 to December 2019, patients with pulmonary infections were prospectively enrolled from the intensive care unit. Factors affecting the meropenem trough concentration were analyzed, and a multiple linear regression model was constructed. Logistic regression analyses were used to investigate the relationship between Ctrough and clinical efficacy. A total of 64 patients were enrolled, in whom 210 meropenem concentrations were measured. Of the total, 60.9% (39/64) were considered clinically successful after treatment. Ctrough may increase with increased blood urea nitrogen, albumin, and concomitant antifungal use. By contrast, concentration may decrease with increased endogenous creatinine clearance rate. Six variables, including Ctrough/minimum inhibitory concentration (MIC) > 4, were associated with the efficacy of meropenem. There was an independent correlation between Ctrough/MIC > 4 and efficacy after fully adjusting for confounding factors. Based upon renal function indexes, it is possible to predict changes in meropenem concentration and adjust the dosage precisely and individually. Ctrough/MIC > 4 is a potential instrument to predict successful treatment with meropenem.
Full article
(This article belongs to the Special Issue Appropriateness of Antibiotics in China - 2nd Volume)
►▼
Show Figures

Figure 1
Open AccessSystematic Review
Public Health Interventions to Improve Antimicrobial Resistance Awareness and Behavioural Change Associated with Antimicrobial Use: A Systematic Review Exploring the Use of Social Media
Antibiotics 2022, 11(5), 669; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050669 - 16 May 2022
Abstract
Introduction: Over the years there have been several interventions targeted at the public to increase their knowledge and awareness about Antimicrobial Resistance (AMR). In this work, we updated a previously published review by Price et al. (2018), on effectiveness of interventions to improve
[...] Read more.
Introduction: Over the years there have been several interventions targeted at the public to increase their knowledge and awareness about Antimicrobial Resistance (AMR). In this work, we updated a previously published review by Price et al. (2018), on effectiveness of interventions to improve the public’s antimicrobial resistance awareness and behaviours associated with prudent use of antimicrobials to identify which interventions work best in influencing public behaviour. Methods: Five databases—Medline (OVID), CINAHL (EBSCO), Embase, PsycINFO, and Cochrane Central Register of Controlled Trials (CENTRAL-OVID)—were searched for AMR interventions between 2017 and 2021 targeting the public. All studies which had a before and after assessment of the intervention were considered for inclusion. Results: In total, 17 studies were found to be eligible for inclusion in the review. Since there was a variety in the study interventions and in particular outcomes, a narrative synthesis approach was adopted for analysis. Whereas each study showed some impact on awareness and knowledge, none measured long-term impact on behaviours towards antibiotic use, awareness, or knowledge. Engagement was higher in interventions which included interactive elements such as games or videos. Social media was not used for recruitment of participants or as a mode of communication in any AMR interventions included in this review.
Full article
(This article belongs to the Section Antibiotics Use and Antimicrobial Stewardship)
►▼
Show Figures

Figure 1
Open AccessArticle
Chitosan Silver and Gold Nanoparticle Formation Using Endophytic Fungi as Powerful Antimicrobial and Anti-Biofilm Potentialities
by
, , , , , , , , and
Antibiotics 2022, 11(5), 668; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050668 - 16 May 2022
Abstract
Nanotechnology is emerging as a new technology with encouraging innovations. Global antibiotic use has grown enormously, with antibiotic resistance increasing by about 80 percent. In view of this alarming situation, intensive research has been carried out into biogenic nanoparticles and their antibacterial, antifungal,
[...] Read more.
Nanotechnology is emerging as a new technology with encouraging innovations. Global antibiotic use has grown enormously, with antibiotic resistance increasing by about 80 percent. In view of this alarming situation, intensive research has been carried out into biogenic nanoparticles and their antibacterial, antifungal, and antitumor activities. Many methods are available to enhance stability and dispersion via peroration of conjugate with a polymer, such as chitosan, and other bioactive natural products. Two marine fungi were isolated and identified as Aspergillus sp. and Alternaria sp. via sequencing of the 16S rRNA gene. In this work, these strains were used to form the conjugation of biogenic silver nanoparticles (AgNPs) from Aspergillus sp. Silv2 extract and gold nanoparticles (AuNPs) from Alternaria sp. Gol2 extracts with chitosan to prepare chitosan–AgNPs and chitosan–AuNP conjugates. A variety of imaging and analytical methods, such as UV–vis, X-ray powder diffraction (XRD), FTIR spectroscopy, transmission electron microscopy (TEM), and scanning electron microscopy (SEM) were utilized to characterize biogenic nanoparticles and conjugates. The biosynthesized Ag and Au nanoparticles along with the prepared conjugates were evaluated for their antimicrobial effects on Gram-negative and Gram-positive bacterial isolates, including Escherichia coli and Staphylococcus aureus. Both chitosan–AgNP and AuNP showed powerful antimicrobial activities compared to the control. On the other hand, chitosan–AgNP conjugation had better antibacterial ctivity than chitosan–AuNPs, which exhibited moderate activity against S. aureus and very low activity against E. coli. Furthermore, the antibiofilm potentials of the prepared conjugates were tested against four biofilm-forming bacteria, including P. aeruginosa, B. subtilis, E. coli, and S. aureus. The obtained results indicate that the chitosan–AgNP showed a promising anti-biofilm activities on all strains, especially S. aureus, while chitosan–AuNP conjugates showed moderate anti-biofilm against B. subtilis and weak activities against the other three strains. These results showed the superiority of chitosan–AgNP as a promising antibacterial as well as biofilm formation inhibitors.
Full article
(This article belongs to the Section Antimicrobial Materials and Surfaces)
►▼
Show Figures

Figure 1
Open AccessReview
An Overview of Antimicrobial Stewardship Optimization: The Use of Antibiotics in Humans and Animals to Prevent Resistance
by
, , , , , , , , , , , , , and
Antibiotics 2022, 11(5), 667; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050667 - 16 May 2022
Abstract
Antimicrobials are a type of agent widely used to prevent various microbial infections in humans and animals. Antimicrobial resistance is a major cause of clinical antimicrobial therapy failure, and it has become a major public health concern around the world. Increasing the development
[...] Read more.
Antimicrobials are a type of agent widely used to prevent various microbial infections in humans and animals. Antimicrobial resistance is a major cause of clinical antimicrobial therapy failure, and it has become a major public health concern around the world. Increasing the development of multiple antimicrobials has become available for humans and animals with no appropriate guidance. As a result, inappropriate use of antimicrobials has significantly produced antimicrobial resistance. However, an increasing number of infections such as sepsis are untreatable due to this antimicrobial resistance. In either case, life-saving drugs are rendered ineffective in most cases. The actual causes of antimicrobial resistance are complex and versatile. A lack of adequate health services, unoptimized use of antimicrobials in humans and animals, poor water and sanitation systems, wide gaps in access and research and development in healthcare technologies, and environmental pollution have vital impacts on antimicrobial resistance. This current review will highlight the natural history and basics of the development of antimicrobials, the relationship between antimicrobial use in humans and antimicrobial use in animals, the simplistic pathways, and mechanisms of antimicrobial resistance, and how to control the spread of this resistance.
Full article
(This article belongs to the Special Issue Optimization of Antimicrobial Stewardship in Public Health)
►▼
Show Figures

Figure 1
Open AccessArticle
Capsaicin Potently Blocks Salmonella typhimurium Invasion of Vero Cells
Antibiotics 2022, 11(5), 666; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics11050666 - 16 May 2022
Abstract
►▼
Show Figures
Salmonella typhimurium (S. typhimurium) is one of the major food and waterborne bacteria that causes several health outbreaks in the world. Although there are few antibiotics against this bacterium, some of these drugs are challenged with resistance and toxicity. To mitigate
[...] Read more.
Salmonella typhimurium (S. typhimurium) is one of the major food and waterborne bacteria that causes several health outbreaks in the world. Although there are few antibiotics against this bacterium, some of these drugs are challenged with resistance and toxicity. To mitigate this challenge, our group explored the ethnomedicinal/herbalism knowledge about a certain spice used in Northern Ghana in West Africa against bacterial and viral infection. This plant is Capsicum chinense (C. chinense). The plant is one of the commonest food spices consumed across the world. The seed of the plant contains both capsaicin and dihydrocapsaicin. Apart from capsaicin and dihydrocapsaicin, other major capsaicinoids in C. chinense include nordihydrocapsaicin, homodihydrocapsaicin, and homocapsaicin. In this pilot work, we investigated the antibacterial activity of pure capsaicin and capsaicin extract obtained from C. chinense against S. typhimurium in vitro. Capsaicin extract showed potent inhibition of S. typhimurium growth at concentrations as low as 100 ng/mL, whereas pure capsaicin comparatively showed poorer inhibition of bacteria growth at such a concentration. Interestingly, both capsaicin extract and pure capsaicin were found to potently block a S. typhimurium invasion of the Vero cell in vitro. Taken together, we believed that capsaicin might work synergistically with dihydrocapsaicin or the other capsaicinoids to inhibit S. typhimurium growth, whereas individually, capsaicin or dihydrocapsaicin could potently block the bacteria entry and invasion of Vero cells.
Full article

Figure 1

Journal Menu
► ▼ Journal Menu-
- Antibiotics Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor's Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal BrowserHighly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
Topic in
Antibiotics, Pharmaceutics, Pharmaceuticals, MPs
Emerging Material-Based Approaches to Chronic and Infectious Diseases
Topic Editors: Alan J. Hibbitts, Sofia A. PapadimitriouDeadline: 31 May 2022
Topic in
Antibiotics, Antioxidants, JoF, Microbiology Research, Microorganisms
Redox in Microorganisms
Topic Editors: Michal Letek, Luis M. Mateos, Volker Behrends, Jesús NavasDeadline: 30 November 2022
Topic in
Challenges, IJMS, Microbiology Research, Pathogens, Vaccines, Antibiotics
Advances in Human Pathogen Control – A 21st Century Challenge
Topic Editors: Jorge H. Leitão, Nitin Amdare, Joana R FelicianoDeadline: 28 February 2023

Conferences
Special Issues
Special Issue in
Antibiotics
Microbiological and Clinical Aspects of Actinomyces Infections
Guest Editors: Edit Urbán, Márió GajdácsDeadline: 31 May 2022
Special Issue in
Antibiotics
Social Dimensions of Antibiotic Resistance in Asia - a One Health Perspective
Guest Editors: Sonia Lewycka, Christopher Pell, Phaik Yeong CheahDeadline: 10 June 2022
Special Issue in
Antibiotics
Seafood and Antibiotics
Guest Editors: Olumide Odeyemi, Deyan StratevDeadline: 30 June 2022
Special Issue in
Antibiotics
Epidemiology of Acquired AmpC Type β-Lactamases in Enterobacteriaceae from a One Health Perspective
Guest Editors: Ângela Novais, Teresa G RibeiroDeadline: 15 July 2022
Topical Collections
Topical Collection in
Antibiotics
Discovery and MultiFunctionality of Anti-Microbial Peptides
Collection Editors: Marc Maresca, Josette Perrier, Michael Lafond
Topical Collection in
Antibiotics
Antimicrobial Resistance and Anti-Biofilms
Collection Editors: Ding-Qiang Chen, Yulong Tan, Ren-You Gan, Guanggang Qu, Zhenbo Xu, Junyan Liu